Porpharma Biologics, a biopharmaceutical company specializing in the development and manufacture of biosimilars, today announced a groundbreaking licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will acquire exclusive commercialization rights for biosimilars for autoimmune diseases in Latin America (LATAM), excluding Brazil.
Porpharma Biologics will continue to assume full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed region. This partnership reflects both companies’ shared commitment to expanding patient access to high-quality, affordable biotherapies in the region.
Anjan Selz, CEO of Polpharma Biologics, said, “Our partnership with Tuteur is an important step forward in our mission to expand access to biosimilars globally. Leveraging their strong regional expertise and commercial capabilities in LATAM, we are well-positioned to bring this important treatment to patients with autoimmune diseases. Together, we aim to improve access to effective and affordable treatment options throughout the region.”
Jonathan Hahn, President of Tuteur, said, “Our collaboration with Polpharma Biologics marks a significant milestone for Tuteur. Partnering with such a capable organization further strengthens our commitment to expanding access to world-class biopharmaceuticals for patients across Latin America.”
This biosimilar, currently under development, is designed to provide an effective and well-tolerated treatment option for patients with autoimmune diseases. Regulatory submissions are planned within the next three years.
About Polpharma Biologics
Porpharma Biologics is a group of biopharmaceutical companies focused on the development and manufacture of biopharmaceuticals and biosimilars for the global market. As a Switzerland-based biosimilar platform, it manages the entire value chain, from product selection and investment allocation to development and commercialization, and works closely with global partners to ensure efficient progress from concept to market. Its biosimilar portfolio comprises multiple programs at various stages of development, from early-stage research to commercialization. Its international team possesses advanced expertise across a wide range of areas, including program management, regulatory strategy, CMC integration, device development, clinical supervision, and quality assurance. Through partnerships with trusted CDMOs, Porpharma Biologics provides comprehensive biosimilar solutions in key therapeutic areas, from cell line development to finished products. By maintaining a strong and expanding biosimilar pipeline, Porpharma Biologics is committed to facilitating access to biotherapeutic drugs worldwide.
For more information: https://polpharmabiologics.com/polpharma-biologics-and-tuteur/
About Tuteur
Tuteur is a leading company in the specialty healthcare sector across Latin America, providing innovative therapies and solutions to address complex medical needs. With a strong focus on patient outcomes, operational excellence, and strategic partnerships, Tuteur combines extensive expertise in the manufacturing and distribution of specialty pharmaceuticals to serve healthcare professionals and patients in the region. Driven by a robust pipeline of specialty therapies and a patient-centered approach, Tuteur continues to expand its presence in LATAM, prioritizing innovation, efficiency, and sustainable growth.
For more information: https://tuteurgroup.com/
The official version of this press release is the original language version. Translated versions are provided for the convenience of the reader and have no legal effect. When using translated versions as reference material, please compare them with the original language version, which is the only legally binding version.
Source link:https://www.businesswire.com/
